Cell-free DNA — Minimally invasive marker of hematological
malignancies

J 2017

Cell-free DNA — Minimally invasive marker of hematological malignancies

KUBACZKOVÁ, Veronika, Dávid VRÁBEL, Lenka SEDLAŘÍKOVÁ, Lenka BEŠŠE, Sabina ŠEVČÍKOVÁ et. al.

Základní údaje

Originální název

Cell-free DNA — Minimally invasive marker of hematological malignancies

Autoři

KUBACZKOVÁ, Veronika (203 Česká republika, domácí), Dávid VRÁBEL (203 Česká republika), Lenka SEDLAŘÍKOVÁ (203 Česká republika, domácí), Lenka BEŠŠE (203 Česká republika) a Sabina ŠEVČÍKOVÁ (203 Česká republika, garant, domácí)

Vydání

European Journal of Haematology, Hoboken, Wiley, 2017, 0902-4441

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.595

Kód RIV

RIV/00216224:14110/17:00095664

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/ejh.12925

UT WoS

000411525900001

Klíčová slova anglicky

acute lymphoblastic leukemia; acute myeloid leukemia; multiple myeloma; myelodysplastic syndromes

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 3. 2018 13:36, Soňa Böhmová

Anotace

V originále

Although tumor cells are the most reliable source of tumor DNA, biopsy of the tumor is an invasive procedure that should be avoided in some cases. The main limitation of any biopsy is sampling of one tumor site, which may not represent all malignant clones due to the heterogeneity of the tumor. These clones respond to treatment differently and thus directly influence survival of the patient. Circulating cell-free DNA (cfDNA) is released from multiple tumor sites, reflects overall heterogeneity of the tumor, and correlates with its progression. Detection of tumor-specific genetic and epigenetic aberrations in cfDNA could have a direct impact on molecular diagnosis, prognosis, follow-up of disease, monitoring of minimal residual disease, and response to treatment. While most cfDNA data are still experimental, they are very promising. This review focuses on cfDNA in hematological malignancies.

Návaznosti

NV15-29508A, projekt VaV

Název: Cirkulující nukleové kyseliny jako markery progrese mnohočetného myelomu

Citovat

KUBACZKOVÁ, Veronika, Dávid VRÁBEL, Lenka SEDLAŘÍKOVÁ, Lenka BEŠŠE a Sabina ŠEVČÍKOVÁ. Cell-free DNA — Minimally invasive marker of hematological malignancies. European Journal of Haematology. Hoboken: Wiley, 2017, roč. 99, č. 4, s. 291-299. ISSN 0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.12925.

@article{1392128,
   author = {Kubaczková, Veronika and Vrábel, Dávid and Sedlaříková, Lenka and Bešše, Lenka and Ševčíková, Sabina},
   article_location = {Hoboken},
   article_number = {4},
   doi = {http://dx.doi.org/10.1111/ejh.12925},
   keywords = {acute lymphoblastic leukemia; acute myeloid leukemia; multiple myeloma; myelodysplastic syndromes},
   language = {eng},
   issn = {0902-4441},
   journal = {European Journal of Haematology},
   title = {Cell-free DNA — Minimally invasive marker of hematological malignancies},
   volume = {99},
   year = {2017}
}

TY  - JOUR
ID  - 1392128
AU  - Kubaczková, Veronika - Vrábel, Dávid - Sedlaříková, Lenka - Bešše, Lenka - Ševčíková, Sabina
PY  - 2017
TI  - Cell-free DNA — Minimally invasive marker of hematological malignancies
JF  - European Journal of Haematology
VL  - 99
IS  - 4
SP  - 291-299
EP  - 291-299
PB  - Wiley
SN  - 09024441
KW  - acute lymphoblastic leukemia
KW  - acute myeloid leukemia
KW  - multiple myeloma
KW  - myelodysplastic syndromes
N2  - Although tumor cells are the most reliable source of tumor DNA, biopsy of the tumor is an invasive procedure that should be avoided in some cases. The main limitation of any biopsy is sampling of one tumor site, which may not represent all malignant clones due to the heterogeneity of the tumor. These clones respond to treatment differently and thus directly influence survival of the patient. Circulating cell-free DNA (cfDNA) is released from multiple tumor sites, reflects overall heterogeneity of the tumor, and correlates with its progression. Detection of tumor-specific genetic and epigenetic aberrations in cfDNA could have a direct impact on molecular diagnosis, prognosis, follow-up of disease, monitoring of minimal residual disease, and response to treatment. While most cfDNA data are still experimental, they are very promising. This review focuses on cfDNA in hematological malignancies.
ER  -

KUBACZKOVÁ, Veronika, Dávid VRÁBEL, Lenka SEDLAŘÍKOVÁ, Lenka BEŠŠE a Sabina ŠEVČÍKOVÁ. Cell-free DNA — Minimally invasive marker of hematological malignancies. \textit{European Journal of Haematology}. Hoboken: Wiley, 2017, roč.~99, č.~4, s.~291-299. ISSN~0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.12925.

Podrobný výpis o publikaci